読み込み中
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
前日終値
$21.50
−$0.28 · -1.29%
日中の時刻はETです。市場データは遅延する場合があります。
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
日中レンジ
現在 $21.50
52週レンジ
現在 $21.50
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
56
適正価値
センチメント
53
まちまち
リスク
75
高リスク
モメンタム
49
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
日中レンジ
現在 $21.50
52週レンジ
現在 $21.50
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 850万 USD | 19.8万 USD | 82.1万 USD | 32.3万 USD | 2000 USD |
| 売上原価 | 25.5万 USD | — | — | — | — |
| 粗利益 | 824.5万 USD | 19.8万 USD | 82.1万 USD | 32.3万 USD | 2000 USD |
| 研究開発 | 553.1万 USD | 2456.6万 USD | 3419.3万 USD | 3545.7万 USD | 3556.8万 USD |
| 販売・一般管理 | 1244.2万 USD | 1776.8万 USD | 2064.1万 USD | 994.7万 USD | 1529.1万 USD |
| 営業費用 | 1771.8万 USD | 4233.4万 USD | 5483.4万 USD | 4540.4万 USD | 5085.9万 USD |
| 受取利息 | 15.2万 USD | 48万 USD | 75.3万 USD | 43.1万 USD | 46.7万 USD |
| 支払利息 | 6.5万 USD | 17.9万 USD | 15万 USD | 9.3万 USD | 8.3万 USD |
| 減価償却費と償却費 | 25.5万 USD | 36.1万 USD | 66.9万 USD | 77.5万 USD | 68.1万 USD |
| 営業利益 | −947.3万 USD | −4213.6万 USD | −5401.3万 USD | −4508.1万 USD | −5085.7万 USD |
| 純利益 | −1093.9万 USD | −5385.8万 USD | −1.73億 USD | −2.41億 USD | −9479.7万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2024年11月25日 | 1:100 | — | — |
発効済み 2024年11月25日
1:100
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
